Back to Search Start Over

Cellular Immune Responses in Islet Xenograft Rejection.

Cellular Immune Responses in Islet Xenograft Rejection.

Authors :
Min Hu
Hawthorne, Wayne J.
Shounan Yi
O'Connell, Philip J.
Source :
Frontiers in Immunology; 7/7/2022, Vol. 13, p1-12, 12p
Publication Year :
2022

Abstract

Porcine islets surviving the acute injury caused by humoral rejection and IBMIR will be subjected to cellular xenograft rejection, which is predominately mediated by CD4<superscript>+</superscript> T cells and is characterised by significant infiltration of macrophages, B cells and T cells (CD4<superscript>+</superscript> and CD8<superscript>+</superscript>). Overall, the response is different compared to the alloimmune response and more difficult to suppress. Activation of CD4<superscript>+</superscript> T cells is both by direct and indirect antigen presentation. After activation they recruit macrophages and direct B cell responses. Although they are less important than CD4<superscript>+</superscript> T cells in islet xenograft rejection, macrophages are believed to be a major effector cell in this response. Rodent studies have shown that xenoantigen-primed and CD4<superscript>+</superscript> T cell-activated macrophages were capable of recognition and rejection of pancreatic islet xenografts, and they destroyed a graft via the secretion of various proinflammatory mediators, including TNF-α, reactive oxygen and nitrogen species, and complement factors. B cells are an important mediator of islet xenograft rejection via xenoantigen presentation, priming effector T cells and producing xenospecific antibodies. Depletion and/or inhibition of B cells combined with suppressing T cells has been suggested as a promising strategy for induction of xenodonor-specific T- and B-cell tolerance in islet xenotransplantation. Thus, strategies that expand the influence of regulatory T cells and inhibit and/or reduce macrophage and B cell responses are required for use in combination with clinical applicable immunosuppressive agents to achieve effective suppression of the T cell-initiated xenograft response. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16643224
Volume :
13
Database :
Complementary Index
Journal :
Frontiers in Immunology
Publication Type :
Academic Journal
Accession number :
158226401
Full Text :
https://doi.org/10.3389/fimmu.2022.893985